Skip to main content
SpringerLink
Log in

A Comparative Assessment of the Risks and Benefits of Zopiclone

A Review of 15 Years’ Clinical Experience

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

This review compares the efficacy of zopiclone with that of a number of commonly used short-, medium- and long-acting benzodiazepines. Zopiclone at dosages of 7.5 mg/day has demonstrated efficacy equivalent and in some cases greater to that of flurazepam 30 mg/day, nitrazepam 5 mg/day, flunitrazepam 1 to 2 mg/day, temazepam 20 mg/day, triazolam 0.125 to 0.5 mg/day and mid-azolam 15 mg/day. Zopiclone-treated patients reported themselves to be less impaired by daytime sedation than patients treated with the medium- and long-acting hypnosedatives flurazepam, nitrazepam and flunitrazepam. Zopiclone and temazepam showed similar effects on daytime behaviour while zopiclone appeared to have somwhat better effects on daytime well-being than the short-acting triazolam and midazolam. There has been no clinical comparison with the frequently used medium-acting benzodiazepines lormetazepam and brotizolam and the imidazopyridine hypnosedative zolpidem. Data from clinical trials, pooled analyses and postmarketing surveillance including over 30 000 patients showed that with the exception of bitter taste (reported by <10% of zopiclone recipients), the tolerability profile of zopiclone is similar to that of placebo. Clinical trials found no evidence for significant rebound insomnia and indicated that the risk of withdrawal reactions with therapeutic doses of zopiclone is very low. In addition, to date, dependency appears very low, although abuse potential should be considered following a history of addiction or psychiatric illness. Evaluation of the accumulated evidence from over 2.5 billion units dispensed in more than 30 countries indicates that zopiclone is effective, well tolerated and an excellent alternative to benzodiazepines in the short term treatment of insomnia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Üstün T, Privett M, LeCrubier Y, et al. Form, frequency, and burden of sleep problems in general health care. Eur J Psychiatry 1996; 11 Suppl. 1: 5S–10S

    Article  Google Scholar 

  2. Simen S, Hajak G, Schlaf G, et al. Chronic sleep complaints. Results of a representative survey in Germany. Nervenarzt 1995; 66: 686–95

    PubMed  CAS  Google Scholar 

  3. National Commission on Sleep Disorders. Wake up America: a national sleep alert. Bethesda (MD): National Institutes of Health, 1993

  4. Ohayon MM, Caulet M. Psychotropic medication and insomnia complaints in two epidemiological studies. Can J Psychiatry 1996; 41: 457–64

    PubMed  CAS  Google Scholar 

  5. von der Schulenburg G. Measuring the unmeasurable: the role and importance of quality of life measurement in economic evaluations of sleep disorder treatment. Eur Psychiatry 1995; 10 Suppl. 3: 95S–8S

    Article  Google Scholar 

  6. Idzikowski C. Impact of insomnia on health-related quality of life. Pharmacoeconomics 1996; 10 Suppl. 1: 15–24

    Article  PubMed  Google Scholar 

  7. Roth T. An overview of the report of the National Commission on Sleep Disorders Research. Eur Psychiatry 1995; 10 Suppl. 3: 109S–13S

    Article  PubMed  Google Scholar 

  8. Chilcott LA, Shapiro CM. The socioeconomic impact of insomnia. Pharmacoeconomics 1996; 10 Suppl. 1: 1–14

    Article  PubMed  Google Scholar 

  9. Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16: 873–97

    PubMed  CAS  Google Scholar 

  10. Costae Silva JA, Chase M, Sartorius N, et al. Special report from a symposium held by the World Health Organization and the World Federation of Sleep Research Societies: an overview of insomnias and related disorders — recognition, epidemiology, and rational management. Sleep 1996; 19: 412–6

    Google Scholar 

  11. Czeisler CA, Richardson GS. Detection and assessment of insomnia. Clin Ther 1991; 13: 663–79

    PubMed  CAS  Google Scholar 

  12. Hajak G. Insomnia in primary care. Sleep (Suppl.). In press

  13. Hajak G, Rüther E. Insomnie. Berlin, Heidelberg: Springer, 1995

    Google Scholar 

  14. Kupfer DJ, Reynolds CF 3rd. Management of insomnia. N Engl J Med 1997; 336(5): 341–6

    Article  PubMed  CAS  Google Scholar 

  15. Ashton H. Guidelines for the rational use of benzodiazepines: when and what to use. Drugs 1994; 48: 25–40

    Article  PubMed  CAS  Google Scholar 

  16. Clarenbach P, Fischer W. Nachtschlaf und Tagesbefinden schlafgestörter Patienten unter Zopiclon: Eine Anwendungsbeobachtung. Psychopharmakotherapie 1995; 2: 6–11

    Google Scholar 

  17. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologium Congress: 1990 Sep 10-14; Kyoto, Japan [abstracts]. Clin Neuropharmacol 1990; 13 Suppl. 2: 1-686

  18. Maczaj M. Pharmacological treatment of insomnia. Drugs 1993; 45: 44–55

    Article  PubMed  CAS  Google Scholar 

  19. Lahmeyer H. Hypnotics: a powerful tool for a serious problem. Pharmacol Ther 1995; 20: 438–55

    Google Scholar 

  20. Roth T, Roehrs T. Areview of the safety profiles of benzodiazepine hypnotic use. J Clin Psychiatry 1991; 52(9 Suppl.): 38–41

    PubMed  Google Scholar 

  21. Roth T, Roehrs TA. Issues in the use of benzodiazepine therapy. J Clin Psychiatry 1992; 53(6 Suppl.): 14–8

    PubMed  Google Scholar 

  22. Mendelson WB, Jain B. An assessment of short-acting hypnotics. Drug Saf 1995; 13: 257–70

    Article  PubMed  CAS  Google Scholar 

  23. Gaillot J, Le Roux Y, Houghton GW, et al. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987; 10Suppl. 1: 7–21

    PubMed  Google Scholar 

  24. Macdonald RL, Olsen RW. GABAA receptor channels. Annu Rev Neurosci 1994; 17: 569–602

    Article  PubMed  CAS  Google Scholar 

  25. Wisden W, Seeburg PH. GABA Areceptorchannels: from subunits to functional entities. Curr Opin Neurobiol 1992; 2: 263–9

    Article  PubMed  CAS  Google Scholar 

  26. Goa KL, Heel RC. Zopiclone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 1986; 32: 48–65

    Article  PubMed  CAS  Google Scholar 

  27. Hindmarch I, Musch B. Zopiclone in clinical practice. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 1–158

    Google Scholar 

  28. Wadworth AN, McTavish D. Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging 1993; 3: 441–59

    Article  PubMed  CAS  Google Scholar 

  29. Noble S, Langtry HD, Lamb HM, et al. Zopiclone: an update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. Drugs 1998; 55: 277–302

    Article  PubMed  CAS  Google Scholar 

  30. Dehlin O, Rubin B, Rundgren A. Double-blind comparison of zopiclone and flunitrazepam in elderly insomniacs with special focus on residual effects. Curr Med Res Opin 1995; 13(6): 317–24

    Article  PubMed  CAS  Google Scholar 

  31. Mouret J, Ruel D, Maillard F, et al. Zopiclone versus triazolam in insomniac geriatric patients: a specific increase in delta sleep with zopiclone. Int Clin Psychopharmacol 1990; Suppl. 2: 47–55

    Google Scholar 

  32. Klimm HD, Dreyfus JF, Delmotte M. Zopiclone versus nitrazepam: a double-blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep 1987; 10 Suppl. 1: 73–8

    PubMed  Google Scholar 

  33. Elie R, Lavoie G, Bourgouin J, et al. Zopiclone versus flurazepam in insomnia: prolonged administration and withdrawal. Int Clin Psychopharmacol 1990; 5: 279–86

    Article  PubMed  CAS  Google Scholar 

  34. Ponciano E, Freitas F, Camara J, et al. A comparison of the efficacy, tolerance and residual effects of zopiclone, fluraze-pam and placebo in insomniac outpatients. Int Clin Psychopharmacol 1990; 5Suppl. 2: 69–77

    PubMed  Google Scholar 

  35. Singh AN, Bourgouin J. Comparison of zopiclone and flurazepam treatments in insomnia. Hum Psychopharm 1990; 5: 217–23

    Article  Google Scholar 

  36. Agnoli A, Manna V, Martucci N. Double-blind study on the hypnotic and antianxiety effects of zopiclone compared with nitrazepam in the treatment of insomnia. Int J Clin Pharmacol Res 1989; 9: 277–81

    PubMed  CAS  Google Scholar 

  37. Anderson AA. Zopiclone and nitrazepam: a multicenterplacebo controlled comparative study of efficacy and tolerance in insomniac patients in general practice. Sleep 1987; 10 Suppl. 1: 54–62

    PubMed  Google Scholar 

  38. Tamminen T, Hansen PP. Chronic administration of zopiclone and nitrazepam in the treatment of insomnia. Sleep 1987; 10 Suppl. 1: 63–72

    PubMed  Google Scholar 

  39. Hajak G, Clarenbach P, Fischer W, et al. Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 1994; 9: 251–61

    Article  PubMed  CAS  Google Scholar 

  40. van Moffaert M, Wilmotte J, Mesters P, et al. Comparison of zopiclone and flunitrazepam in the treatment of insomnia in depressed patients. Curr Ther Res 1990; 48: 140–53

    Google Scholar 

  41. Hajak G, Clarenbach P, Fischer W, et al. Effects of hypnotics on sleep quality and daytime well-being. Data from a comparative multicentre study in outpatients with insomnia. Eur Psychiatr 1995; 10 Suppl. 3: 173S–9S

    Article  Google Scholar 

  42. Ngen CC, Hassan R. A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia. Int Clin Psychopharmacol 1990; 5: 165–71

    Article  PubMed  CAS  Google Scholar 

  43. van der Kleijn E. Effects of zopiclone and temazepam on sleep, behaviour and mood during the day. Eur J Clin Pharmacol 1989; 36: 247–51

    Article  PubMed  Google Scholar 

  44. Wheatley D. Zopiclone: a non-benzodiazepine hypnotic. Controlled comparison to temazepam in insomnia. Br J Psychiatry 1985; 146: 312–4

    Article  PubMed  CAS  Google Scholar 

  45. Chaudoir PJ, Bodkin NL, O’Donnell J, et al. A comparative study of zopiclone and triazolam in patients with insomnia. Int Clin Psychopharmacol 1990; 5Suppl. 2: 21–7

    PubMed  Google Scholar 

  46. Fleming JA, McClure DJ, Mayes C, et al. A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia. Int Clin Psychopharmacol 1990; 5Suppl. 2: 29–37

    PubMed  Google Scholar 

  47. Hayoun G, Bagot C. Comparative efficacy and safety of triazolam and zopiclone in insomniacs seen in general practice. Curr Ther Res 1989; 46: 1236–44

    Google Scholar 

  48. Elie R, Frenay M, Le Morvan P, et al. Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs. Int Clin Psychopharmacol 1990; 5Suppl. 2: 39–46

    PubMed  Google Scholar 

  49. Fontaine R, Beaudry P, Le Morvan P. Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 1990; 5: 173–83

    Article  PubMed  CAS  Google Scholar 

  50. Autret E, Maillard F, Autret A. Comparison of the clinical hypnotic effects of zopiclone and triazolam. Eur J Clin Pharmacol 1987; 31: 621–3

    Article  PubMed  CAS  Google Scholar 

  51. Begg EJ, Robson RA, Frampton CM, et al. A comparison of efficacy and tolerance of the short acting sedatives midazolam and zopiclone. N Z Med J 1992; 105: 428–9

    PubMed  CAS  Google Scholar 

  52. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40: 291–313

    Article  PubMed  CAS  Google Scholar 

  53. Hoehns JD, Perry PJ. Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 1993; 12: 814–28

    PubMed  CAS  Google Scholar 

  54. Freeman H, Puech AJ, Roth T, editors. Zolpidem: an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier, 1996

    Google Scholar 

  55. Quadens OP, Hoffman G, Buytaert G. Effects of zopiclone as compared to flurazepam on sleep in women over 40 years of age. Pharmacology 1983; 27 Suppl. 2: 146–55

    Article  PubMed  Google Scholar 

  56. Jovanovic UJ, Dreyfus JF. Polygraphical sleep recordings in insomniac patients under zopiclone or nitrazepam. Pharmacol 1983; 27Suppl 2: 136–45

    Article  Google Scholar 

  57. Tiberge M, Calvet U, Khayi N, et al. Comparison of the effects of zopiclone and triazolam on the sleep of normal subjects [in French]. Encephale 1988; 14(4): 319–24

    PubMed  CAS  Google Scholar 

  58. Gillin JC, Spinweber CL, Johnson LC. Rebound insomnia: a critical review. J Clin Psychopharmacol 1989; 9: 161–72

    Article  PubMed  CAS  Google Scholar 

  59. Kales A, Scharf MB, Kales JD, et al. Rebound insomnia: a potential hazard following withdrawal of certain benzodiazepines. JAMA 1979; 241: 1692–5

    Article  PubMed  CAS  Google Scholar 

  60. Lader M. Rebound insomnia and newer hypnotics. Psychopharmacology 1992; 108: 248–55

    Article  PubMed  CAS  Google Scholar 

  61. Pecknold J, Wilson R, Le Morvan P. Long term efficacy and withdrawal of zopiclone: a sleep laboratory study. Int Clin Psychopharmacol 1990; 5Suppl. 2: 57–67

    PubMed  Google Scholar 

  62. Kummer J, Gündel L, Seyffer B. Effects of zopiclone on sleep-EEG and daytime well-being in the elderly [abstract]. Eur Psychiatry 1994; 9 Suppl. 1: 138

    Google Scholar 

  63. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs 1998; 10: 425–40

    Article  CAS  Google Scholar 

  64. Dobbins SE. Zimovane — a post marketing surveillance in general practice — interim report [abstract]. J Psychopharmacol 1992; 6: 131

    Google Scholar 

  65. Musch B, Maillard F. In: Hindmarch I, Musch B, editors. Zopiclone in clinical practice. London: Clinical Neuroscience Publishers, 1990: 147

    Google Scholar 

  66. Bianchi M, Musch B. Zopiclone discontinuation: review of 25 studies assessing withdrawal and rebound phenomena. Int Clin Psychopharmacol 1990; 5 Suppl. 2: 139–45

    PubMed  Google Scholar 

  67. Roehrs T, Vogel G, Roth R. Rebound insomnia: its determinants and significance. Am J Med 1990; 88 Suppl. 3A: 395–425

    Google Scholar 

  68. Hajak G, Clarenbach P, Fischer W, et al. Rebound insomnia in insomniac outpatients. Eur Arch Gen Psy Neurol Sci 1998; 248: 148–56

    CAS  Google Scholar 

  69. Inman W, Kubota K, Pearce G, et al. PEM report number 10: zopiclone. Pharmacoepidemiol Drug Saf 1993; 2: 499–521

    Article  Google Scholar 

  70. Lemoine P, Ohayon MM. Is hypnotic withdrawal facilitated by the transitory use of a substitute drug? Prog Neuro-psychopharmacol Biol Psychiatry 1997; 21(1): 111–24

    Article  CAS  Google Scholar 

  71. Pat-Horenczyk R, Hacohen D, Herer P, et al. The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics. Psychopharmacology (Berl) 1998 Dec; 140(4): 450–7

    Article  CAS  Google Scholar 

  72. Thakore J, Dinan TG. Physical dependence following zopiclone usage: acase report. Hum Psychopharm 1992; 7: 143–5

    Article  Google Scholar 

  73. Jones IR, Sullivan G. Physical dependence on zopiclone: case reports [letter]. BMJ 1998; 316: 117

    Article  PubMed  CAS  Google Scholar 

  74. Sikdar S, Ruben SM. Zopiclone abuse among polydrug users. Addiction 1996 Feb; 91: 285–6

    Article  PubMed  CAS  Google Scholar 

  75. Sullivan G, McBride AJ, Clee WB. Zopiclone abuse in South Wales: three case reports. Hum Psychopharm 1995;10: 351–2

    Article  Google Scholar 

  76. Ayonrinde O, Sampson E. Physical dependence on zopiclone. Risk of dependence may be greater in those with dependent personalities [letter]. BMJ 1998; 317(7151): 146

    PubMed  CAS  Google Scholar 

  77. Sikdar S. Physical dependence on zopiclone. Prescribing this drug to addicts may give rise to iatrogenic drug misuse. BMJ 1998; 317(7151): 146

    Article  PubMed  CAS  Google Scholar 

  78. Lemoine P, Allain H, Janus C, et al. Gradual withdrawal of zopiclone (7.5 mg) and zolpidem (10 mg) in insomniacs treated for at least 3 months. Eur Psychiatry 1995; 10 Suppl. 3: 161–5

    Article  Google Scholar 

  79. Goldenberg F, Hindmarch I, Joyce CRB, et al. Zopiclone, sleep and health-related quality of life. Hum Psychopharmacol 1994; 9: 245–51

    Article  Google Scholar 

  80. O’Hanlon JF. Zopiclone’s residual effects on psychomotor and information processing skills involved in complex tasks such as car driving: acritical review. Eur Psychiatr 1995; 10 Suppl. 3: 137S–43S

    Article  Google Scholar 

  81. Bocca ML, Le Doze F, Etard O, et al. Residual effect of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades. Psychopharmacology (Berl) 1999; 143(4): 373–9

    Article  CAS  Google Scholar 

  82. Fossen A, Godlibsen OB, Loyning Y, et al. Effects of hypnotics on memory. Int Pharmacopsychiatry 1982; 17 Suppl. 2: 116–26

    PubMed  CAS  Google Scholar 

  83. Mattila MJ, Vanakoski J, Kalska H, et al. Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav 1998; 59(4): 917–23

    Article  PubMed  CAS  Google Scholar 

  84. Allain H, Delahaye C, Le Coz F, et al. Postmarketing surveillance of zopiclone in insomnia: analysis of 20, 513 cases. Sleep 1991; 14: 408–13

    PubMed  CAS  Google Scholar 

  85. De la Calzada Alvarez D, Sanchez Navarro J. Zopiclone: estudio de postcomercialización en España. Psiquis 1994; 15: 17–24

    Google Scholar 

  86. Dataon file. Rhone-Poulenc Rorer, 1999

  87. Boniface PJ, Russell SG. Two cases of fatal zopiclone overdose. J Anal Toxicol 1996; 20: 131–3

    PubMed  CAS  Google Scholar 

  88. Meatherall RC. Zopiclone fatality in a hospitalized patient. J Forensic Sci 1997; 42: 340–43

    PubMed  CAS  Google Scholar 

  89. Lader M. Zopiclone: is there any dependence and abuse potential? J Neurol 1997 Apr; 244(4 Suppl. 1): S18–22

    Article  PubMed  CAS  Google Scholar 

  90. Lader M. Anxiolytic drugs: dependence, addiction and abuse. Eur Neuropsychopharmacol 1994; 4: 85–91

    Article  PubMed  CAS  Google Scholar 

  91. Hajak G, Rodenbeck A. Clinical management of patients with insomnia: the role of zopiclone. Pharmacoeconomics 1996; 10 Suppl. 1: 29–38

    Article  PubMed  CAS  Google Scholar 

  92. Janknegt R, van der Kuy A, Declerck G, et al. Hypnotics: drug selection by means of the System of Objectified Judgement Analysis (SOJA) method. Pharmacoeconomics 1996; 10: 152–63

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Georg-August-University of Göttingen, von-Siebold-Strasse 5, 37075, Göttingen, Germany

    Göran Hajak

Authors
  1. Göran Hajak
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hajak, G. A Comparative Assessment of the Risks and Benefits of Zopiclone. Drug-Safety 21, 457–469 (1999). https://doi.org/10.2165/00002018-199921060-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199921060-00003

Keywords

Search

Navigation